Jeffrey Testani, MD, MTR
Associate Professor of MedicineCards
Appointments
Additional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Appointments
Additional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Appointments
Additional Titles
Director of Heart Failure Research, Cardiovascular Medicine
Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Contact Info
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
About
Titles
Associate Professor of Medicine
Director of Heart Failure Research, Cardiovascular Medicine; Co-Director Heart & Vascular Center Clinical Research, Heart & Vascular Center
Biography
My clinical training is as an advanced heart failure physician with formal research training in patient oriented translational research. My research program is supported by NIH and investigator-initiated industry sources and uses techniques of both translational and clinical research to further the mechanistic understanding of cardiac-renal interactions, fluid and sodium homeostasis, and diuretic resistance. The primary approach of my current research program is prospective mechanistic human studies in heart failure and kidney disease patients, for which we have established extensive infrastructure. N My lab has extensive expertise in biomarker research has established and maintains an extensive bioassay resource with the capability to determine an extensive range of analytes in human biological samples with complexity ranging from simple serum chemistries to complex analytes such as ultra-trace lithium by inductively coupled plasma mass spectrometry, deuterium concentration by IRMS, high dimension multiplex protein assays, and large and small molecules by liquid chromatography mass spectrometry.
Appointments
Cardiovascular Medicine
Associate Professor on TermPrimary
Other Departments & Organizations
- Cardiovascular Medicine
- Heart Failure Program
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Cardiovascular Research Center (YCVRC)
- Yale Medicine
- Yale Ventures
Education & Training
- Fellowship
- Hospital of the University of Pennsylvania (2012)
- MS
- University of Pennsylvania Medical School (2012)
- Research Fellowship
- Hospital of the University of Pennsylvania (2011)
- Fellowship
- Hospital of the University of Pennsylvania (2009)
- Residency
- Hospital of the University of Pennsylvania (2007)
- Internship
- Hospital of the University of Pennsylvania (2005)
- MD
- University of Florida (2004)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0001-5285-0419
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
F. Perry Wilson, MD, MSCE
Veena Rao, PhD
Christopher Maulion, MD
Jeffrey Turner, MD
Dennis G Moledina, MD, PhD, FASN
Harlan Krumholz, MD, SM
Heart Failure
Diuretics
Sodium
Cardio-Renal Syndrome
Kidney Diseases
Publications
2024
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.
Siddiqi T, Cherney D, Siddiqui H, Jafar T, Januzzi J, Khan M, Levin A, Marx N, Rangaswami J, Testani J, Usman M, Wanner C, Zannad F, Butler J. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. Journal Of The American Society Of Nephrology 2024 PMID: 39230974, DOI: 10.1681/asn.0000000000000491.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitusChronic kidney diseaseEffects of sodium-glucose cotransporter-2 inhibitorsComposite kidney endpointCotransporter-2 inhibitorsKidney outcomesHeart failureKidney diseaseKidney endpointsHazard ratioDoubling of serum creatinineCombination of heart failureSustained doubling of serum creatininePlacebo-controlled trialReduced ejection fractionBaseline heart failureConfidence intervalsRandom-effects modelAlbuminuria progressionEjection fractionSerum creatinineReview ManagerMellitusPatientsEffects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF
Bhatt A, Bhatt D, Steg P, Szarek M, Cannon C, Leiter L, McGuire D, Lewis J, Riddle M, Voors A, Metra M, Lund L, Testani J, Wilcox C, Davies M, Pitt B, Kosiborod M. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF. Journal Of The American College Of Cardiology 2024, 84: 1078-1088. PMID: 39260929, DOI: 10.1016/j.jacc.2024.06.036.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSodium-glucose cotransporter 2Effect of sotagliflozinKCCQ-12 scoreKCCQ-12Heart failureSOLOIST-WHFPrimary endpointSodium-glucose cotransporter 2 inhibitionLeft ventricular ejection fractionWorsening heart failureBaseline to monthVentricular ejection fractionHealth statusWorsening HFKansas City Cardiomyopathy Questionnaire-12Ejection fractionSecondary endpointsCotransporter 2Randomized patientsClinical characteristicsHF hospitalizationPlaceboCardiovascular deathHF episodeSotagliflozinInpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems
Zheng J, Sandhu A, Bhatt A, Collins S, Flint K, Fonarow G, Fudim M, Greene S, Heidenreich P, Lala A, Testani J, Varshney A, Wi R, Ambrosy A. Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Failure 2024 PMID: 39269395, DOI: 10.1016/j.jchf.2024.08.004.Peer-Reviewed Original ResearchAltmetricConceptsCommunity-based health systemQuality improvement registryHealth systemGuideline-directed medical therapyGuideline-directed medical therapy useEligible hospitalsImprovement registryNational quality improvement registryElectronic health record dataHealth record dataEvidence-based medicationsHF hospitalizationHeart failurePostdischarge strategiesHFrEF patientsFailure hospitalizationMedical therapyCommunity-basedAngiotensin receptor-neprilysin inhibitorSodium-glucose cotransporter 2 inhibitorsInpatient useRecord dataRenin-angiotensin system inhibitorsMineralocorticoid receptor antagonistsWorsening renal functionMechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchAltmetricConceptsTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightThe utility of urine sodium–guided diuresis during acute decompensated heart failure
Siddiqi H, Cox Z, Stevenson L, Damman K, ter Maaten J, Bales B, Han J, Ivey-Miranda J, Lindenfeld J, Miller K, Ooi H, Rao V, Schlendorf K, Storrow A, Walsh R, Wrenn J, Testani J, Collins S. The utility of urine sodium–guided diuresis during acute decompensated heart failure. Heart Failure Reviews 2024, 29: 1161-1173. PMID: 39128947, PMCID: PMC11455821, DOI: 10.1007/s10741-024-10424-8.Peer-Reviewed Original ResearchAltmetricConceptsAcute decompensated heart failureDecompensated heart failureHeart failureClinical trialsUrine sodium excretionObservational cohort studyRandomized clinical trialsAdequate decongestionDiuretic strategySodium excretionUrine chemistryCohort studyTitration strategyUrineDiuretic titrationAdverse effectsDiuresisDecongestionPatientsUsual careEvidence gapsTrialsTherapyFailureDapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Tada A, Burkhoff D, Naser J, Harada T, Pourmussa B, Reddy Y, Jensen M, Carter R, Demmer R, Testani J, Chirinos J, Borlaug B. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial. Circulation 2024, 150: 997-1009. PMID: 39101201, PMCID: PMC11433515, DOI: 10.1161/circulationaha.124.068788.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSystemic arterial complianceEffects of dapagliflozinStressed blood volumeVenous capacitanceBlood volumePeak exerciseArterial complianceHemodynamic congestionHeart failureEstimating stressed blood volumeImproved systemic arterial complianceInvasive hemodynamic exercise testingSodium-glucose cotransporter-2 inhibitorsSystolic BPPulmonary capillary wedge pressureHemodynamic exercise testingCapillary wedge pressureCotransporter-2 inhibitorsSystemic vascular resistanceImproving clinical outcomesTotal blood volumeRadial artery pressureSimultaneous echocardiographyEjection fractionFluid-filled catheterPeak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Kidney International Reports 2024, 9: 3035-3044. PMID: 39430198, PMCID: PMC11489825, DOI: 10.1016/j.ekir.2024.07.009.Peer-Reviewed Original ResearchAltmetricConceptsLeft ventricular ejection fractionPulmonary artery pressureCreatinine doublingEGFR declineEjection fractionKidney outcomesHeart failurePeak tricuspid regurgitant jet velocityDoubling of serum creatinineTricuspid regurgitant jet velocityElevated pulmonary artery pressureAssociated with lower eGFRWorsening kidney functionVentricular ejection fractionRegurgitant jet velocityCox proportional hazards modelsProportional hazards modelPost hoc analysisBaseline eGFRSerum creatinineLow eGFRTOPCAT trialFollow-upKidney functionArterial pressureIncreased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does Not Enhance Decongestion
Natov P, Ivey-Miranda J, Cox Z, Rao V, Butler J, Konstam M, Kiernan M, Kapur N, Testani J. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does Not Enhance Decongestion. Journal Of Cardiac Failure 2024 PMID: 38986838, DOI: 10.1016/j.cardfail.2024.06.008.Peer-Reviewed Original ResearchAltmetricConceptsBaseline serum potassiumAcute heart failureSerum potassiumSpironolactone treatmentTreatment armsHeart failureBaseline serum potassium levelsNatriuretic peptide levelsTreated with spironolactoneSerum potassium levelsSpironolactone-treated patientsNet fluid lossRenal potassium handlingPost hoc analysisEnhance decongestionSpironolactone dosePotassium wastingUrine outputClinical congestionTreatment startPotassium handlingPotassium replacementPotassium supplementationPharmacodynamic effectsSurrogate markerEffects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction
Naser J, Tada A, Harada T, Reddy Y, Carter R, Testani J, Jensen M, Borlaug B. Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circulation 2024, 149: 2026-2028. PMID: 38885297, PMCID: PMC11185269, DOI: 10.1161/circulationaha.124.069479.Peer-Reviewed Original ResearchCitationsAltmetricVolenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial
San Tham L, Heerspink H, Wang X, Verdino P, Saifan C, Benson E, Goldsmith P, Wang Z, Testani J, Haupt A, Sam F, Cherney D. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial. Nephrology Dialysis Transplantation 2024, gfae112. PMID: 38782726, DOI: 10.1093/ndt/gfae112.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMeasured glomerular filtration rateEffective renal plasma flowRenal plasma flowKidney perfusionIncreased renal plasma flowPlacebo-adjusted changeMultiple-ascending dosePhase 1 trialGlomerular filtration rateChronic heart failureChronic kidney diseaseDiastolic blood pressureRenal arteriolar resistanceExtended half-lifeCardiorenal functionDouble-blindPlacebo SCRelaxin proteinSC doseAdverse eventsMeasured GFRArteriolar resistanceClinical developmentHeart failureOrthostatic hypotension
Clinical Trials
Current Trials
Mechanisms of Diuretic Resistance in Heart Failure (MsDR)
HIC ID2000032328RolePrincipal InvestigatorPrimary Completion Date03/31/2028Recruiting ParticipantsGenderBothAge18+ yearsErtugliflozin in Acute Heart Failure
HIC ID2000027951RolePrincipal InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
activity Reprieve cardiovascualr
Advisory BoardsAdvisorDetailsReprieve CardiovascularClinical trial steering committee09/01/2020 - Presentactivity Boehringer Ingelheim
Advisory BoardsAdvisorDetailsBoehringer IngelheimEmpagliflozin Scientific Advisory Board2019 - Presentactivity Cardionomic
Advisory BoardsAdvisorDetailsCardionomicClinical trial steering committee2019 - Presentactivity 3ive Labs
Advisory BoardsAdvisorDetails3ive LabsClinical trial steering committee08/01/2021 - Presentactivity Lilly
Advisory BoardsAdvisorDetailsLillyClinical trial steering committee and co-PI08/01/2021 - Present
Clinical Care
Overview
Jeffrey Testani, MD, MTR (master of science in translational research) is a cardiologist who specializes in advanced heart failure. People with advanced heart failure experience shortness of breath and other symptoms even while at rest despite conventional therapies and strategies.
Dr. Testani’s work focuses on the connections between fluid build-up and heart failure. When the heart is unable to pump an adequate supply of blood to the body, the kidneys respond by increasing the volume of fluids. Dr. Testani and fellow researchers have determined that a diabetes medication can reduce fluid build-up in diabetic patients with heart failure.
Dr. Tetany’s current research involves studying hundreds of heart patients, producing 500,000 biospecimens, or samples, that can be used to determine specific paths and characteristics that lead to heart failure.
Dr. Testani is an associate professor of medicine (cardiology) at Yale School of Medicine.
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- October 25, 2024
Can a ‘Kidney Action Team’ Improve Patient Outcomes?
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- February 26, 2024
Reanalyzing the Impact of COVID-19 on the Kidneys
- July 13, 2023
Department of Internal Medicine Promotions and Appointments (July 2023)
Get In Touch
Contacts
Cardiovascular Medicine
PO Box 208017
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.